Compare AMC ENTERTAINMENT HOLDINGS, INC. (AMC) vs Moderna, Inc. (MRNA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AMC ENTERTAINMENT HOLDINGS, INC. vs Moderna, Inc. — how do they compare? AMC ENTERTAINMENT HOLDINGS, INC. trades at $1.88 (market cap $1.69B), while Moderna, Inc. trades at $67.98 (market cap $27.09B). The key difference: Moderna, Inc. is far larger — about 16× AMC ENTERTAINMENT HOLDINGS, INC.'s market cap, and AMC ENTERTAINMENT HOLDINGS, INC. pays a 0.11% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| AMC | MRNA | |
|---|---|---|
Market Cap | $1.69B | $27.09B |
Sector | Media | Health |
52-Week High | $3.54 | $81.80 |
52-Week Low | $0.95 | $22.36 |
Enterprise Value | $9.28B | $23.18B |
Dividend Yield | 0.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMC trades at $1.89, down 0.53% on the day, with mixed technical signals showing a bullish moving average trend but neutral oscillators. The company reported Q1 2026 EPS of -$0.36, missing expectations, while revenue trends show modest growth from $4.6B in 2024 to $4.85B in 2025. Recent news highlights box office recovery optimism and a $200 million stock offering that caused dilution concerns.
Outlook remains challenging with persistent net losses and high debt burden, though analyst consensus targets $1.90 with 32% buy ratings. Key risks include ongoing dilution from equity offerings, competitive pressures in entertainment, and the need for sustained box office recovery to improve cash flow and profitability.
Moderna (MRNA) trades at $68.27, down 10.83% amid a biotech sell-off, but maintains a bullish technical trend with strong moving averages. Revenue has declined from pandemic peaks to $1.92B in 2025, with net losses widening to -$2.82B, yet recent quarterly EPS beats and pipeline expansions into oncology and flu vaccines fuel optimism. The stock remains volatile, with a consensus price target of $49.00 below the current price, reflecting mixed analyst sentiment.
The outlook hinges on pipeline execution, with EU RSV vaccine contracts and FDA decisions offering upside, but high cash burn and competitive pressures pose risks. Investors face a trade-off between growth potential and profitability challenges, with the stock's 70% monthly surge testing sustainability near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AMC ENTERTAINMENT HOLDINGS, INC.
AMC Entertainment Holdings, Inc. operates as a holding company. The Company, through its subsidiaries, provides theatrical exhibition, movie screening, food distribution, online ticket booking, and other related services. AMC Entertainment offers movie theaters worldwide.
Read more on AMC →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
